Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2024

Genmab — Januar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #1149

    Er der mig, eller var der liiidt styrke i aktien idag ? Vil være dejlig hvis vi kan komme i 2000 inden regnskab og få en buffer ned til 1901 når markedet bliver åhh så overraskede over ny højere omkostninger til de mange ph3 trials

    1 Reply Last reply
    0
    • W Offline
      W Offline
      w
      wrote on sidst redigeret af
      #1150

      Kan være markedet har ændret holdning til dyre fase 3 forsøg i positiv retning,
      efter voldgiften

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #1151

        Mon ikke man vil nervøs indtil regnskab og specielt guidance foreligger. Man anser jo R&D for en katastrofe.

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #1152

          Jo fase 3 forsøgene er jo en nødvendighed, særligt nu da voldgiften er tabt og burde blive belønnet som et fremskridt. Gmab skal jo bare huske at highlighte deres succesrate. Så bliver det jo så godt som money in the bank 🙂 Men guidance skal helst bekræfte den fortsat kraftige vækst

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bikube
            wrote on sidst redigeret af
            #1153

            Både Genmab og Novo fortsatte op i USA

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #1154

              from
              Scancell Interim Results for the six months ended 31 October 2023- Antibodies:
              • Development of SC129, out licensed to Genmab, continues on track towards potential clinical
              development.
              https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/2024/scancell-interim-results-31-october-2023.pdf

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #1155

                Novel Cervical Cancer Treatments in Clinical Trial https://news.med.miami.edu/novel-cervical-cancer-treatments-in-clinical-trial/ “The antibody drug conjugate tisotumab vedotin-tftv has also gained approval and became a standard-of-care therapy this year. This therapy extends survival significantly,” said Dr. Sinno.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1156

                  Pfizer
                  earnings later today will give us full year Tiso sales

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #1157

                    Tivdak had list price changes this year of 3,90% 30-3-2023
                    and 3,90%
                    28-9-2023

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1158

                      so, pfizer reports $4mn for Tivdak under Represents revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023. So now we have to find the remainder of the quarter 4 sales somewhere lol, Seagen doesn't report anymore

                      1 Reply Last reply
                      0
                      • M Offline
                        M Offline
                        M_T_A
                        wrote on sidst redigeret af
                        #1159

                        Pfizer skriver at FDA har accepteret Tivdak sBLA ansøgning om konvertering fra "accelerated approval" til fuld godkendelse med priority review og PDUFA dato d. 9 maj, se link side 8. 2024.https://s28.q4cdn.com/781576035/files/doc_financials/2023/q4/Q4-2023-PFE-Earnings-Release.pdf

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          lahn1
                          wrote on sidst redigeret af
                          #1160

                          Håber det giver himmelfart til kursen 🙂

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            Plimsoller
                            wrote on sidst redigeret af
                            #1161

                            Svar fra Andrew Carlsen angående stilleperioden "Our quiet period before earnings is still 2 weeks and has not been extended to 4 weeks with the US listing."

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1162

                              thanks Plimsoller

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                Plimsoller
                                wrote on sidst redigeret af
                                #1163

                                You are welcome.

                                1 Reply Last reply
                                0
                                • JørgenVarnæsJ Offline
                                  JørgenVarnæsJ Offline
                                  JørgenVarnæs
                                  wrote on sidst redigeret af
                                  #1164

                                  Egentlig en meget subtil måde at spørge “hvad f#€&”€en i h#€”&€&€lvede foregår der!?”

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #1165

                                    Maybe not a good sign:

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #1166

                                      The third Pfizer product to hit the reject pile is PF-07260437, a phase 1 therapy designed to treat advanced breast cancer, ovarian cancer or endometrial cancer. The B7-H4 x CD3 bispecific monoclonal antibody was being tested among 30 patients in a study that wrapped in October of last year, as listed on ClinicalTrials.gov.

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #1167

                                        Just a moment...

                                        favicon

                                        (www.fiercebiotech.com)

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #1168

                                          Godt eller dårligt? En konkurrent mindre eller går gen1047 samme vej?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper